Free Trial

Krystal Biotech (KRYS) Competitors

Krystal Biotech logo
$194.70 +1.72 (+0.89%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

KRYS vs. SMMT, ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, and VRNA

Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

Krystal Biotech vs. Its Competitors

Krystal Biotech (NASDAQ:KRYS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Krystal Biotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$359.21M15.69$89.16M$4.9239.57
Summit Therapeutics$700K24,717.80-$221.32M-$1.01-23.06

Krystal Biotech has a net margin of 40.85% compared to Summit Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 15.21% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech40.85% 15.21% 13.81%
Summit Therapeutics N/A -208.64%-181.28%

In the previous week, Summit Therapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for Summit Therapeutics and 7 mentions for Krystal Biotech. Summit Therapeutics' average media sentiment score of 0.78 beat Krystal Biotech's score of 0.39 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Summit Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Krystal Biotech has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500.

Krystal Biotech presently has a consensus target price of $209.00, indicating a potential upside of 7.34%. Summit Therapeutics has a consensus target price of $31.29, indicating a potential upside of 34.32%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Summit Therapeutics
4 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

Krystal Biotech beats Summit Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRYS vs. The Competition

MetricKrystal BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.64B$3.37B$6.12B$10.45B
Dividend YieldN/A2.30%5.73%4.78%
P/E Ratio39.5822.7785.3227.36
Price / Sales15.69486.78603.66198.22
Price / Cash40.5546.7037.4661.86
Price / Book5.9210.5512.566.81
Net Income$89.16M-$52.58M$3.32B$276.80M
7 Day Performance3.15%0.09%0.63%0.42%
1 Month Performance26.12%15.61%10.55%7.86%
1 Year Performance9.52%15.13%75.10%41.24%

Krystal Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRYS
Krystal Biotech
4.3787 of 5 stars
$194.71
+0.9%
$209.00
+7.3%
+8.1%$5.64B$359.21M39.58210Analyst Revision
SMMT
Summit Therapeutics
2.8544 of 5 stars
$22.15
+3.4%
$31.29
+41.2%
+3.7%$15.92B$700K-21.93110Analyst Upgrade
ASND
Ascendis Pharma A/S
3.2124 of 5 stars
$210.83
+3.3%
$244.36
+15.9%
+62.7%$12.59B$393.54M-40.861,017News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume
VTRS
Viatris
2.3253 of 5 stars
$10.13
-0.6%
$10.40
+2.7%
-15.7%$11.88B$14.74B-3.4932,000News Coverage
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.908 of 5 stars
$14.12
-0.3%
$16.95
+20.0%
-11.0%$11.82B$3.81B21.3927,811News Coverage
Positive News
MRNA
Moderna
4.2635 of 5 stars
$27.54
-3.3%
$41.81
+51.8%
-51.6%$11.08B$3.24B-3.665,800
ROIV
Roivant Sciences
3.0723 of 5 stars
$16.26
+0.6%
$19.94
+22.6%
+43.0%$11.04B$29.05M-23.23860Insider Trade
QGEN
QIAGEN
4.2983 of 5 stars
$46.99
+0.4%
$49.40
+5.1%
+11.5%$10.40B$1.98B27.765,765
ELAN
Elanco Animal Health
2.6612 of 5 stars
$20.68
+0.2%
$18.33
-11.3%
+47.1%$10.25B$4.44B24.059,000Analyst Revision
BBIO
BridgeBio Pharma
4.2233 of 5 stars
$54.61
+3.3%
$63.94
+17.1%
+123.1%$10.11B$221.90M-13.35400Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
1.4602 of 5 stars
$106.91
+0.1%
$109.00
+2.0%
N/A$9.20B$42.28M-107.9930Positive News

Related Companies and Tools


This page (NASDAQ:KRYS) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners